Shingrix Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Herpes zoster vaccine [varicella zoster virus glycoprotein E (non-live, recombinant, AS01_B adjuvanted)]

Indications/Uses

Prevention of herpes zoster & post-herpetic neuralgia in adults ≥50 yr; adults ≥18 yr at increased risk of herpes zoster.

Click to view Shingrix detailed prescribing information

Dosage/Direction for Use

IM Primary vaccination schedule 2 doses of 0.5 mL each, initial dose followed by 2nd dose 2 mth later. If necessary, 2nd dose can be administered between 2 & 6 mth after 1st dose. Immunodeficient or immunosuppressed individual 2nd dose can be given 1-2 mth after initial dose.

Click to view Shingrix detailed prescribing information

Overdosage

View Shingrix overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Shingrix detailed prescribing information

Special Precautions

Not to be administered intravascularly, intradermally or SC. Not indicated for prevention of primary varicella infection (chickenpox); not intended for treatment of established clinical disease. Postpone vaccination in subjects suffering from acute severe febrile illness. Thrombocytopenia or any coagulation disorder; syncope (fainting). May affect ability to drive & use machines. Pregnancy & lactation. Childn & adolescents. Increased risk of Guillain-Barré syndrome in elderly ≥65 yr.

Click to view Shingrix detailed prescribing information

Use In Pregnancy & Lactation

Click to view Shingrix detailed prescribing information

Adverse Reactions

Headache; GI symptoms including nausea, vomiting, diarrhoea &/or abdominal pain; myalgia; inj site reactions (eg, pain, redness, swelling), fatigue, chills, fever. Inj site pruritus, malaise.

Click to view Shingrix detailed prescribing information

Drug Interactions

Administer at different inj sites w/ another inj vaccine. More frequent adverse reactions of fever & shivering w/ PPV23 vaccine.

Click to view Shingrix detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Shingrix detailed prescribing information

Storage

View Shingrix storage conditions for details to ensure optimal shelf-life.

Description

View Shingrix description for details of the chemical structure and excipients (inactive components).

Action

View Shingrix mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BK - Varicella zoster vaccines ; Used for active immunizations.

Regulatory Classification

Presentation/Packing

Form

Shingrix powd & susp for susp for inj (vial) 50 mcg/dose

Packing/Price

10's;1's

Shingrix

recombinant varicella-zoster virus glycoprotein e antigen vaccine

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma